The activity of thalidomide in patients with relapsed or refractory multiple myeloma has been well confirmed. However, plasmacytomas were less responsive to thalidomide and extramedullary progression despite serological response has been observed. We described a case of massive liver involvement in a patient treated with thalidomide; we suggest that extramedullary progression could due to a clone selection induced by treatment.
|Number of pages||3|
|Publication status||Published - Apr 2003|
- Extramedullary progression
- Multiple myeloma
ASJC Scopus subject areas